Search results for "Drugs"

showing 10 items of 747 documents

Cancer combination therapies with artemisinin-type drugs

2017

Artemisia annua L. is a Chinese medicinal plant, which is used throughout Asia and Africa as tea or press juice to treat malaria. The bioactivity of its chemical constituent, artemisinin is, however, much broader. We and others found that artemisinin and its derivatives also exert profound activity against tumor cells in vitro and in vivo. Should artemisinin-type drugs be applied routinely in clinical oncology in the future, then it should probably be as part of combination therapy regimens rather than as monotherapy. In the present review, I give a comprehensive overview on synergistic and additive effects of artemisinin-type drugs in combination with different types of cytotoxic agents an…

0301 basic medicineDrugCombination therapymedicine.medical_treatmentmedia_common.quotation_subjectArtemisia annuaDrug resistancePharmacologyBiochemistry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivoCell Line TumorNeoplasmsAntineoplastic Combined Chemotherapy Protocolsparasitic diseasesmedicineAnimalsHumansDrug InteractionsArtemisininmedia_commonPharmacologyBiological ProductsChemotherapyNatural productbiologybusiness.industryDrug SynergismDrugs Investigationalbiology.organism_classificationAntineoplastic Agents PhytogenicCombined Modality TherapyArtemisininsDrug Resistance Multiple030104 developmental biologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisChemical and Drug Induced Liver InjurybusinessSesquiterpenesmedicine.drugBiochemical Pharmacology
researchProduct

Shikonin derivatives for cancer prevention and therapy.

2019

Abstract Phytochemicals gained considerable interest during the past years as source to develop new treatment options for chemoprevention and cancer therapy. Motivated by the fact that a majority of established anticancer drugs are derived in one way or another from natural resources, we focused on shikonin, a naphthoquinone with high potentials to be further developed as preventive or therapeutic drug to fight cancer. Shikonin is the major chemical component of Lithospermum erythrorhizon (Purple Cromwell) roots. Traditionally, the root extract has been applied to cure dermatitis, burns, and wounds. Over the past three decades, the anti-inflammatory and anticancer effects of root extracts, …

0301 basic medicineDrugModels MolecularCancer Researchmedicine.medical_treatmentmedia_common.quotation_subject03 medical and health sciencesStructure-Activity Relationship0302 clinical medicineNeoplasmsMedicineAnimalsHumansmedia_commonCancer preventionTraditional medicinebiologybusiness.industryCancerImmunotherapyLithospermum erythrorhizonbiology.organism_classificationmedicine.diseaseAntineoplastic Agents PhytogenicClinical trialRadiation therapy030104 developmental biologyOncologyPhytochemical030220 oncology & carcinogenesisbusinessDrugs Chinese HerbalNaphthoquinonesCancer letters
researchProduct

Kinase Inhibitors in Multitargeted Cancer Therapy

2017

The old-fashioned anticancer approaches, aiming in arresting cancer cell proliferation interfering with non-specific targets (e.g. DNA), have been replaced, in the last decades, by more specific target oriented ones. Nonetheless, single-target approaches have not always led to optimal outcomes because, for its complexity, cancer needs to be tackled at various levels by modulation of several targets. Although at present, combinations of individual single-target drugs represent the most clinically practiced therapeutic approaches, the modulation of multiple proteins by a single drug, in accordance with the polypharmacological strategy, has become more and more appealing. In the perspective of…

0301 basic medicineDrugNiacinamideIndolesPyridinesmedia_common.quotation_subjectPharmacologyBioinformaticsBiochemistryReceptor tyrosine kinase03 medical and health sciencesCrizotinibPiperidinesMultitargeted drugs anticancer agents polypharmacology tyrosine kinase receptors oncogene addiction tumor microenvironment FDA-approved drugsNeoplasmsDrug DiscoverymedicineSunitinibHumansAnilidesPyrrolesProtein Kinase Inhibitorsmedia_commonPharmacologyTumor microenvironmentbiologybusiness.industryPhenylurea CompoundsOrganic ChemistryImidazolesCancerReceptor Protein-Tyrosine KinasesSorafenibmedicine.diseaseOncogene AddictionSettore CHIM/08 - Chimica FarmaceuticaClinical trialPyridazines030104 developmental biologyMechanism of actionbiology.proteinImatinib MesylateQuinazolinesMolecular MedicinePyrazolesmedicine.symptombusinessTyrosine kinase
researchProduct

Drugs Polypharmacology by in Silico Methods: New Opportunities in Drug Discovery

2016

Background Polypharmacology, defined as the modulation of multiple proteins rather than a single target to achieve a desired therapeutic effect, has been gaining increasing attention since 1990s, when industries had to withdraw several drugs due to their adverse effects, leading to permanent injuries or death, with multi-billiondollar legal damages. Therefore, if up to then the "one drug one target" paradigm had seen many researchers interest focused on the identification of selective drugs, with the strong expectation to avoid adverse drug reactions (ADRs), very recently new research strategies resulted more appealing even as attempts to overcome the decline in productivity of the drug dis…

0301 basic medicineDrugPolypharmacologymedia_common.quotation_subjectIn silicoNanotechnology03 medical and health sciencesBiological and chemical databases computational methods Drugs multitarget activity polypharmacology repurposingDrug DiscoveryMedicineHumansComputer SimulationPolypharmacologyRepurposingmedia_commonPharmacologyMolecular Structurebusiness.industryDrug discoveryDrug repositioningIdentification (information)030104 developmental biologyRisk analysis (engineering)businessChemical databaseSoftware
researchProduct

Advances in drug-induced cholestasis: Clinical perspectives, potential mechanisms and in vitro systems

2018

Despite growing research, drug-induced liver injury (DILI) remains a serious issue of increasing importance to the medical community that challenges health systems, pharmaceutical industries and drug regulatory agencies. Drug-induced cholestasis (DIC) represents a frequent manifestation of DILI in humans, which is characterised by an impaired canalicular bile flow resulting in a detrimental accumulation of bile constituents in blood and tissues. From a clinical point of view, cholestatic DILI generates a wide spectrum of presentations and can be a diagnostic challenge. The drug classes mostly associated with DIC are anti-infectious, anti-diabetic, anti-inflammatory, psychotropic and cardiov…

0301 basic medicineDrugmedicine.drug_classmedia_common.quotation_subjectReceptors Cytoplasmic and NuclearMiscellaneous DrugsIn Vitro TechniquesToxicologyBioinformaticsBile flow03 medical and health sciences0302 clinical medicineCholestasismedicineAnimalsBileHumansDrug induced cholestasismedia_commonCholestasisPolymorphism GeneticBile acidbusiness.industryMembrane Transport ProteinsGeneral Medicinemedicine.diseaseGastrointestinal MicrobiomeMicroRNAs030104 developmental biologyCardiovascular agent030211 gastroenterology & hepatologyChemical and Drug Induced Liver InjurybusinessFood ScienceHealthcare systemFood and Chemical Toxicology
researchProduct

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective.

2020

International audience; Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug targets which have been studied intensively in the past few decades. Although several drugs have been approved in this field, they are still limited to a subset of hematological malignancies (in particular T-cell lymphomas), with therapeutic potential not fully realized and the drug-resistance occurred after a certain period of use. To maximize the therapeutic potential of these classes of anticancer drugs, and to extend their application to solid tumors, numerous combination therapies containing an HDACi and an anticancer agent from other mechanisms are currently ongoing in clin…

0301 basic medicineDual targeting[SDV]Life Sciences [q-bio]Cancer therapyKinasesAntineoplastic AgentsBioinformaticsBiochemistryAnticancer drugsSynergistic effectsHistone Deacetylases03 medical and health sciences0302 clinical medicineDrug Delivery SystemsNeoplasmsReceptorsmedicineAnimalsHumansEpigeneticsPharmacologybiologybusiness.industryCancerDUAL (cognitive architecture)medicine.diseaseAnticancer drug3. Good healthEnzymesClinical trial[SDV] Life Sciences [q-bio]Histone Deacetylase Inhibitors030104 developmental biologyHistone030220 oncology & carcinogenesisbiology.proteinHistone deacetylases (HDACs)EpigeneticsDual inhibitorbusinessBiochemical pharmacology
researchProduct

Biosynthesis of heme O in intraerythrocytic stages of Plasmodium falciparum and potential inhibitors of this pathway

2019

A number of antimalarial drugs interfere with the electron transport chain and heme-related reactions; however, the biosynthesis of heme derivatives in Plasmodium parasites has not been fully elucidated. Here, we characterized the steps that lead to the farnesylation of heme. After the identification of a gene encoding heme O synthase, we identified heme O synthesis in blood stage parasites through the incorporation of radioactive precursors. The presence of heme O synthesis in intraerythrocytic stages of Plasmodium falciparum was confirmed by mass spectrometry. Inabenfide and uniconazole–P appeared to interfere in heme synthesis, accordingly, parasite growth was also affected by the additi…

0301 basic medicineErythrocytesANIMAIS PARASITOS030231 tropical medicinePlasmodium falciparumProtozoan Proteinslcsh:MedicineHemePlasmodiumArticle03 medical and health scienceschemistry.chemical_compoundAntimalarials0302 clinical medicinePrenylationBiosynthesisBiophysical chemistryParasite physiologyparasitic diseasesHumansHeme O synthesislcsh:ScienceHemeGeneMultidisciplinaryAlkyl and Aryl TransferasesbiologyInhibitorslcsh:RPlasmodium falciparumbiology.organism_classificationHeme OElectron transport chainPlasmodium Falciparum030104 developmental biologychemistryBiochemistrylcsh:QPlasmodium parasitesAntimalarial drugs
researchProduct

Effects of exposure to gadolinium on the development of geographically and phylogenetically distant sea urchins species.

2016

Gadolinium (Gd), a metal of the lanthanide series used as contrast agent for magnetic resonance imaging, is released into the aquatic environment. We investigated the effects of Gd on the development of four sea urchin species: two from Europe, Paracentrotus lividus and Arbacia lixula, and two from Australia, Heliocidaris tuberculata and Centrostephanus rodgersii. Exposure to Gd from fertilization resulted in inhibition or alteration of skeleton growth in the plutei. The similar morphological response to Gd in the four species indicates a similar mechanism underlying abnormal skeletogenesis. Sensitivity to Gd greatly varied, with the EC50 ranging from 56 nM to 132 μM across the four species…

0301 basic medicineGadoliniumved/biology.organism_classification_rank.specieschemistry.chemical_elementGadolinium010501 environmental sciencesAquatic ScienceEcotoxicologyOceanography01 natural sciencesParacentrotus lividusEnvironmental impact03 medical and health sciencesDevelopmental abnormalityEchinoid; Embryos; Skeletogenesis; Developmental abnormality; Medical drugs; Ecotoxicology; Environmental impactbiology.animalEcotoxicologyAnimalsCentrostephanus rodgersiiSettore BIO/06 - Anatomia Comparata E CitologiaArbacia lixulaSea urchin0105 earth and related environmental sciencesArbaciaLarvabiologyEcologyved/biologyGeneral Medicinebiology.organism_classificationPollutionPhylogeographySkeletogenesi030104 developmental biologyMedical drugchemistryEmbryoAquatic environmentSea UrchinsParacentrotusEchinoidWater Pollutants ChemicalEnvironmental MonitoringMarine environmental research
researchProduct

Selective Cytotoxic Activity of Prodigiosin@halloysite Nanoformulation

2020

Prodigiosin, a bioactive secondary metabolite produced by Serratia marcescens, is an effective proapoptotic agent against various cancer cell lines, with little or no toxicity toward normal cells. The hydrophobicity of prodigiosin limits its use for medical and biotechnological applications, these limitations, however, can be overcome by using nanoscale drug carriers, resulting in promising formulations for target delivery systems with great potential for anticancer therapy. Here we report on prodigiosin-loaded halloysite-based nanoformulation and its effects on viability of malignant and non-malignant cells. We have found that prodigiosin-loaded halloysite nanotubes inhibit human epithelia…

0301 basic medicineHistologylcsh:BiotechnologyBiomedical EngineeringBioengineering02 engineering and technologyhalloysite nanotubesengineering.materialHalloysiteProdigiosin03 medical and health scienceschemistry.chemical_compoundcomet assaylcsh:TP248.13-248.65Cytotoxic T cellcancerOriginal Researchgenotoxic effectanti-cancer drugsbiologyChemistryBioengineering and Biotechnology021001 nanoscience & nanotechnologybiology.organism_classificationmalignant cellsComet assay030104 developmental biologyprodigiosinDrug deliveryToxicitySerratia marcescensdrug deliveryCancer researchengineering0210 nano-technologyDrug carrierBiotechnologyFrontiers in Bioengineering and Biotechnology
researchProduct

Maternal Caloric Restriction Implemented during the Preconceptional and Pregnancy Period Alters Hypothalamic and Hippocampal Endocannabinoid Levels a…

2016

Journal Article; Exposure to inadequate nutritional conditions in critical windows of development has been associated to disturbances on metabolism and behavior in the offspring later in life. The role of the endocannabinoid system, a known regulator of energy expenditure and adaptive behaviors, in the modulation of these processes is unknown. In the present study, we investigated the impact of exposing rat dams to diet restriction (20% less calories than standard diet) during pre-gestational and gestational periods on: (a) neonatal outcomes; (b) endocannabinoid content in hypothalamus, hippocampus and olfactory bulb at birth; (c) metabolism-related parameters; and (d) behavior in adult mal…

0301 basic medicineLitter (animal)hippocampuschemistry.chemical_compoundBehavioral Neuroscience0302 clinical medicineMaternal urdernutrition:Phenomena and Processes::Metabolic Phenomena::Body Composition::Body Fat Distribution::Adiposity [Medical Subject Headings]rathypothalamus:Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Reproductive Physiological Processes::Reproduction::Pregnancy [Medical Subject Headings]Original Research:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Adaptation Psychological [Medical Subject Headings]Endocannabinoid systemOlfactory BulbEndocannabinoidesNeuropsychology and Physiological PsychologyAdiposidadGestationmedicine.symptomRestricción calórica:Chemicals and Drugs::Lipids::Fatty Acids::Fatty Acids Unsaturated::Arachidonic Acids [Medical Subject Headings]medicine.medical_specialtyOffspringEmbarazo:Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Energy Intake::Caloric Restriction [Medical Subject Headings]Cognitive NeuroscienceHypothalamusBiologyDevelopmentlcsh:RC321-57103 medical and health sciencesAnsiedadRatasHyppocampusInternal medicinemedicineHipocampoÁcidos araquidónicos:Anatomy::Nervous System::Central Nervous System::Brain::Limbic System::Hippocampus [Medical Subject Headings]endocannabinoids:Psychiatry and Psychology::Behavior and Behavior Mechanisms::Emotions::Anxiety [Medical Subject Headings]lcsh:Neurosciences. Biological psychiatry. NeuropsychiatrydevelopmentPregnancyPalmitoylethanolamideBehavior:Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Neurotransmitter Agents::Endocannabinoids [Medical Subject Headings]behaviorMetabolismo Energético:Phenomena and Processes::Metabolic Phenomena::Metabolism::Energy Metabolism [Medical Subject Headings]maternal undernutrition:Anatomy::Nervous System::Central Nervous System::Brain::Limbic System::Hypothalamus [Medical Subject Headings]medicine.diseaseAdaptación psicológicaOlfactory bulb030104 developmental biologyEndocrinologyMetabolism:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Rodentia::Muridae::Murinae::Rats [Medical Subject Headings]chemistryRatWeight gainmetabolism030217 neurology & neurosurgeryHipotálamoEndocannabinoidsNeuroscienceFrontiers in Behavioral Neuroscience
researchProduct